Molybdän compositum

Tablets Composition:

1 tablet cont.: Natrium molybdaenicum D3 15 mg; Zincum gluconicum D3, Magnesium asparaginicum D3, Ferrum fumaricum D4, Cobaltum gluconicum D4, Cerium oxalicum D4, Kalium asparaginicum D4, Manganum gluconicum D4, Cuprum sulfuricum D6, Niccolum aceticum D8, Rubidium chloratum D8, Sulfur D6, Phosphorus D6 3 mg each. Indications:

Regulation of the mineral equilibrium.

Dosage:

In general initially 1 tablet left to dissolve under the tongue with or without water daily, subsequently every 2nd day.

Package sizes:

Packs containing 50 and 250 tablets.

Pharmacological and clinical notes

Natrium molybdaenicum (sodium molybdate)

Important trace element, essential constituent of the enzyme xanthine oxydase (Schardinger enzyme).

Zincum gluconicum (zinc gluconate)

Constituent of cells and tissue fluids; important for the normal course of numerous metabolic processes (prosthetic group of carbonic anhydrase, tissue phosphatases, insulin).

Magnesium asparaginicum (magnesium aspartate)

Magnesium, next to potassium, is the most mportant intracellular cation; activates the widest variety of enzyme systems, influences ossification processes, the metabolism of the musculature, membrane permeability and erythropoiesis.

Ferrum fumaricum (iron fumarate)

Vital component of the organism, i.e. in enzymes, e.g. cytochrome oxydase, catalase and peroxidase; further, in haemoglobin,

myoglobin and in the cytochromes; in the iron-fumaric acid compound, with the  function of the citric acid cycle as the special objective.

Cobaltum gluconicum (cobalt gluconate)

Especially as constituent of Vitamin B12, antianaemic action. Cerium oxalicum (cerium oxalate)

Sedative action in gastric and intestinal catarrh, kinetosis. Kalium asparaginicum (potassium aspartate)

Stimulative harmonization of the intra- and extracellular distribution of electrolytes (sodium-potassium pump).

Manganum gluconicum (manganese gluconate)

Activation of various enzyme processes, particularly redox reactions; influence on the respiration of the epidermal cells; promotion of the defensive mechanism against infection.

Cuprum sulfuricum (copper sulphate)

Contributory effect in haemoglobin action, catalytic action in redox processes and in enzyme systems, cramp of the smooth and striped muscles.

Niccolum aceticum (nickel acetate)

Similar action to manganese, cobalt and copper; stimulation of blood coagulation. Rubidium chloratum (rubidium chloride)

Similar action to potassium; promotes the liberation of adrenalin; promotes the functioning of some enzymes (dehydrogenase, acetyl phosphatase).

Sulfur (sulphur)

Reagent in all chronic diseases; cellular activity is influenced catalytically. Phosphorus (phosphorus)

Remedy for affections of the parenchyma; damage to the liver parenchyma.

Based on the individual homoeopathic constituents of Molybdän compositum, therapeutical possibilities result for the regulation of the mineral balance.

By means of Molybdän compositum, therefore, an influence is exerted on the mineral equilibrium and, indeed, on deficient enzyme regulation and enzyme blocking.

This effect is intensified by the mutual amplification of the individual constituents according to Bürgi’s principle, i.e. through the combination effect of molybdenum, zinc, magnesium, iron, cobalt, cerium, potassium, manganese, copper, nickel, rubidium, sulphur and phosphorus, when the coupling to organic acids (aspartic acid, gluconic acid, fumaric acid, etc.) favours the channelling into the cells or into the region of the enzymes.

The action of Molybdän compositum is strengthened by preparations which act upon enzymes, such as Coenzyme compositum and Ubichinon compositum, also by Composita-Heel, etc., which are directed towards similar dysfunctions. The action of all biotherapeutic agents is intensified to some extent by regulation of the trace element level and, in accordance with Bürgi’s principle, in the combination effect, many favourable side effects are produced.

The dosage is adjusted according to the disease, the clinical picture and the stage of the illness.

Molybdän compositum can be administered as trace element preparation both in the short term in daily doses and in general, in rarer doses: 1 tablet about every 2nd or 3rd day.

One starts with 1 tablet daily (for 3 to 4 days; when well tolerated and there are no unfavourable side effects, also for a longer period, of about 8 to 10 days). Then 1  tablet is administered, only 2 to 3 times weekly and later, possibly only once weekly.

Trace elements, however, should not be given in overdoses, as they can then have a toxic effect. According to our experience, a dosage of 0.015 mg sodium molybdate per tablet is sufficient for substitution, and in combination with the above constituents, should be restricted to rare doses.

If any undesirable or unexplained symptoms appear, it is beneficial to suspend medication for 3 to 5 days, followed by a reduction in dosage.

With the usual dosage, no undesirable side effects are known. However, interactions with other preparations, including biotherapeutic agents, cannot always be excluded, when a mutual intensification occurs according to Bürgi’s principle, with possibly excessive reactions. A suspension of medication for several days clarifies the  biological situation. In many cases, 1 tablet weekly is sufficient as maintenance dose. In serious dyscrasia, however, at least temporarily for 1 to 3 weeks, daily doses may  be beneficial (and possibly necessary). As the organism suffering from cancer is deficient in molybdenum, in certain cases, provided that it is well tolerated, 1 tablet daily can even be administerd through many weeks.